[go: up one dir, main page]

JPH0212443B2 - - Google Patents

Info

Publication number
JPH0212443B2
JPH0212443B2 JP60087988A JP8798885A JPH0212443B2 JP H0212443 B2 JPH0212443 B2 JP H0212443B2 JP 60087988 A JP60087988 A JP 60087988A JP 8798885 A JP8798885 A JP 8798885A JP H0212443 B2 JPH0212443 B2 JP H0212443B2
Authority
JP
Japan
Prior art keywords
skin
cells
glucose
sodium chloride
osmotic pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60087988A
Other languages
Japanese (ja)
Other versions
JPS61246130A (en
Inventor
Hajime Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPAN FUAIN KEMIKARU KK
Original Assignee
JAPAN FUAIN KEMIKARU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JAPAN FUAIN KEMIKARU KK filed Critical JAPAN FUAIN KEMIKARU KK
Priority to JP60087988A priority Critical patent/JPS61246130A/en
Publication of JPS61246130A publication Critical patent/JPS61246130A/en
Publication of JPH0212443B2 publication Critical patent/JPH0212443B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

(産業上の利用分野) 本発明は水性皮膚及び毛髪化粧料に係り、皮膚
細胞に対しての電解質バランス、浸透圧バランス
を応用して皮膚細胞を活性化し、皮膚細胞の細胞
機能低下による諸疾患を改善するもので、特に、
沈着色素の除去、赤ら顔の解消、発毛及び脱臭作
用を促進すべくした水性皮膚及び毛髪化粧料に関
するものである。 (従来の技術) 近年、外用剤に関する技術の進歩は著しく、数
多くの外用剤が開発されており、その多くはメチ
ルセルローズ、界面活性剤、合成樹脂エマルジヨ
ン、粉体等を加え、その使用目的によつてクリー
ム状、粘稠状となし、更には水溶液として使用さ
れている。 また、塩化ナトリウム等の無機塩や、ブドウ糖
等の天然糖、或いは血漿などは、夫々単体として
化粧品や医薬品の配合材として広く使用されてい
る。 そして、外用剤として期待される効果は、皮
膚の殺菌、消毒作用、皮膜作用、皮膚の水分
の蒸発を防止しての保湿の促進作用等である。 例えば、塩化ナトリウム等を含んだ肌を和らげ
るクリームに関するものが、U.S.P.3574854号公
報に記載され、また、ミネラル塩類を含んだ皮膚
を衛生的にする出願は、西独国特許出願公開第
3327840号明細書に見られる。更に、グルコース
等を混合した肌を滑らかにする糖の成分に関する
出願として、U.S.P.3859436号公報に記載され、
また、シエービング用デキストラン水溶液に関す
る出願は、U.S.P.3777597号公報に記載されてい
る。 (発明が解決しようとする問題点) ところが、これら従来の外用剤では、皮膚殺菌
及び皮膚の保護の目的が達せられても、皮膚の毛
細血管の循環及び機能低下による皮膚疾患、例え
ば色素沈着症、水虫、インキン、タムシ、ワキ
ガ、脱毛症、フケ、かゆみ等の皮膚細胞分裂機能
低下による諸疾患を改善することは困難であつ
た。 例えば、塩化ナトリウムは、体液浸透圧形成の
主体を成し、特に、0.9%溶液は、医薬品として
重要である。しかしながら、この濃厚溶液は、皮
膚及び粘膜を刺激するが、皮膚から吸収されるこ
とはなく、かえつて脱水作用を受ける。したがつ
て、塩化ナトリウムを添加した外用剤では、皮膚
を刺激したり殺菌はできても、皮膚の水分の蒸発
を防止しての保湿の促進作用等を改善することは
難しい。 また、ブドウ糖は、栄養源となり、グリコーゲ
ンを高め、全身の細胞機能を亢進し、生体の代謝
機能を増し、解毒作用もある。ところが、このブ
ドウ糖は、経口的栄養補給薬とするほか、静脈注
射又は筋肉注射により体内に補給されるものであ
る。したがつて、皮膚へ直接塗布する外用剤へ、
ブドウ糖を添加しても、これらのブドウ糖特有の
効果は、あまり期待できないものであつた。 更に、血漿は、その皮膚透過性の性質から、化
粧品基材に配合されるが、その腐敗を防止し、性
状を保持せしめるためには、ポリエチレングリコ
ールを主成分とした基材に配合する必要があつた
(特公昭34−1000号公報参照)。そして、血漿の成
分を外用剤へ配合するには、ポリエチレングリコ
ールの重量比を少なくとも60%に以上に保つ必要
がある。したがつて、このポリエチレングリコー
ルに血漿を配合して腐敗を防止した場合には、外
の成分を配合しようとしても、重量比として40%
をこえる配合はできない不都合があつた。 そこで、本発明は、叙上のような従来存した諸
事情に鑑み、これらを改善すべく創出されたもの
であり、皮膚細胞間質液と同様な環境を皮膚表面
に作り出し、電解質バランス、浸透圧バランスを
応用することで、皮膚の表層からも障害細胞の正
常化を促進するものであり、皮膚細胞に対する電
解質バランス、浸透圧バランスを応用して皮膚細
胞の活性促進を図るものとし、シミ、赤ら顔の場
合は皮下細胞を刺激、分裂させ、治癒に導びき、
また、頭皮、ワキガ等に対しては浸透圧作用によ
り毛母細胞を刺激し、発毛及び脱臭作用を促進さ
せる水性皮膚及び毛髪化粧料を提供することを目
的とするものである。 (問題点を解決するための手段) 次に、前記した技術的課題を解決するための具
体的構成を説明するに、本発明は、以下に述べる
理由を基礎にしているものである。 すなわち、人間の皮膚における病変である炎
症、色素沈着、脱毛症等の各種症状の原因は、紫
外線、化学物質等の種々の因子が関連したものと
なつており、その細胞レベルでの変化が限られて
いるその根本は、細胞内小器官の一つであるミト
コンドリアの膜や細胞膜の障害といえるものであ
る。つまり、ミトコンドリアの膜の障害によつて
細胞内呼吸の阻害が生じ、これによつて、細胞の
活動源たるATP(アデノシン3リン酸)の産生が
低下する。このようなATPの不足によつて細胞
膜の能動輸送の機能が低下し、細胞と間質液との
間の物質の輸送能力の低下が起る。すると、細胞
内のグルコース等の栄養物質の不足を生じさせ、
ひいてはATPの産生の低下につながるといつた
悪循環をなすものである。 以上のような細胞レベルでの変化を生じさせる
原因は多様なものがあり、特に、皮膚の細胞にお
いては、先天性異常を除外した多の場合は毛細血
管の病変や、圧迫等による血行障害によるもの、
生理的物質の高度の蓄積による浸透圧の恒常性障
害によるもの、これら両者が混合したもの等が原
因として考えられている。 したがつて、このような障害原因を除去すれ
ば、細胞は正常な活動を営むことが可能になるも
のである。特に、表皮の細胞の場合には、外界と
接する性質を有するが故に障害が生じやすく、ま
た、それによつて細胞の活性が低下することにな
り、その結果、生体自体が備えている自然治癒力
による回復が困難になりやすい状況が考えられる
のである。 そこで、本発明は、このような状況を改善する
ために、皮膚細胞間質液と同様な環境を皮膚表面
に作り出し、電解質バランス、浸透圧バランスを
応用することで、皮膚の表層からも障害細胞の正
常化を促進するものであり、そのため、本発明
は、塩化ナトリウム、ブドウ糖、デキストランの
各成分を、50〜60℃の温度で水相成分に溶融した
ものである。 本発明による塩化ナトリウムの配合量は、皮膚
に対する浸透圧バランス、電解質バランスの有効
性、すなわち、皮膚細胞を活性化できるよう、全
体の重量比で1〜10%とする。 次に、ブドウ糖の配合量は、前記無機塩と同様
な理由により、全体の重量比で20〜30%とする。 更に、デキストランの配合量は、全体の重量比
で5〜30%とする。 水相成分は、化粧品を含む通常の外用剤の製造
時に使用される水に溶ける油分、例えばプロピレ
ングリコール、ジプロピレングリコール等は一切
含有せず、純水のみで製造するノンオイルのもの
である。 そして、これらの塩化ナトリウム、ブドウ糖、
デキストランの各成分と水相成分との混合物に際
しては、各成分の溶解を完全にするために、50〜
60℃の温度で実施する。 (作用) 本発明は以上のように構成されており、これが
ため、皮膚に刺激を与えず、その溶液を表皮に塗
布残留させることにより、浸透圧の応用で皮下細
胞に組織液を循環させ、皮下細胞の活性分裂の促
進によつて種々の皮膚疾患を改善できるのであ
る。したがつて、今日まで治癒改善が困難であつ
た外用皮膚疾患、例えば白癬菌によつて発生する
諸疾患である色素沈着症、男女脱毛症等に有効で
ある。 (実施例) 塩化ナトリウム 10%(重量比) ブドウ糖 25% デキストラン 30% 以上の成分を50〜60℃の温度で水35%(重量
比)に混合して溶解させ、水溶液とした。 本発明外用剤の効能を検出するため、上述の組
成からなる外用剤を製造し、色素沈着症、赤ら顔
に悩んでいる成人女子、脱毛症に悩んでいる成人
男子の夫々30名に6ケ月に及ぶ効能試験を実施し
た。 (効能結果) これによる効果を、あり…2点、ややあり…1
点、なし…0点としてその点数を算出し、有効性
を(合計点/60)×100で表示した結果は次表の通
りである(なお、表中の( )付の数値は有効性
を示す)。
(Industrial Application Field) The present invention relates to aqueous skin and hair cosmetics, which activate skin cells by applying electrolyte balance and osmotic pressure balance to the skin cells, and various diseases caused by decreased cell function of skin cells. In particular,
The present invention relates to an aqueous skin and hair cosmetic that is intended to remove deposited pigments, eliminate redness, promote hair growth, and deodorize effects. (Prior art) In recent years, the technology for external use has made remarkable progress, and many external preparations have been developed, many of which contain methylcellulose, surfactants, synthetic resin emulsions, powders, etc. It is used in cream, viscous, and even aqueous solutions. Furthermore, inorganic salts such as sodium chloride, natural sugars such as glucose, or blood plasma are widely used individually as ingredients for cosmetics and pharmaceuticals. The effects expected as an external preparation include skin sterilization, antiseptic action, film action, and promotion of moisturization by preventing evaporation of skin water. For example, a skin soothing cream containing sodium chloride etc. is described in USP 3,574,854, and an application for skin hygiene containing mineral salts is published in West German Patent Application Publication No.
Seen in specification No. 3327840. Furthermore, it is described in USP No. 3,859,436 as an application regarding a sugar component that smoothes the skin by mixing glucose etc.
Further, an application regarding an aqueous dextran solution for shaving is described in USP 3,777,597. (Problems to be Solved by the Invention) However, even if these conventional external preparations achieve the purpose of skin sterilization and skin protection, they may cause skin diseases such as hyperpigmentation due to decreased circulation and function of skin capillaries. It has been difficult to improve various diseases caused by decreased skin cell division function, such as athlete's foot, ink, calluses, armpit moth, alopecia, dandruff, and itching. For example, sodium chloride plays a major role in forming osmotic pressure in body fluids, and 0.9% solutions are particularly important as pharmaceuticals. However, although this concentrated solution irritates the skin and mucous membranes, it is not absorbed through the skin and instead has a dehydrating effect. Therefore, although external preparations containing sodium chloride can irritate the skin and sterilize the skin, it is difficult to prevent the evaporation of moisture from the skin and improve the moisturizing effect. Glucose also serves as a nutritional source, increases glycogen, enhances cell function throughout the body, increases the metabolic function of the body, and has a detoxifying effect. However, in addition to being used as an oral nutritional supplement, this glucose is also supplied into the body by intravenous or intramuscular injection. Therefore, for external preparations that are applied directly to the skin,
Even when glucose was added, these effects specific to glucose could not be expected. Furthermore, plasma is incorporated into cosmetic base materials due to its skin-permeable property, but in order to prevent its spoilage and maintain its properties, it is necessary to incorporate it into base materials containing polyethylene glycol as its main component. Atsuta (see Special Publication No. 34-1000). In order to incorporate plasma components into external preparations, it is necessary to maintain the weight ratio of polyethylene glycol at least 60%. Therefore, if blood plasma is mixed with this polyethylene glycol to prevent spoilage, even if you try to mix other ingredients, the weight ratio will be 40%.
There was an inconvenience that it was not possible to mix more than Therefore, the present invention was created in order to improve these problems in view of the existing circumstances as described above. By applying pressure balance, it promotes the normalization of damaged cells even from the surface layer of the skin, and by applying electrolyte balance and osmotic pressure balance to skin cells, it aims to promote the activity of skin cells. In the case of a red face, it stimulates and divides subcutaneous cells, leading to healing.
Another object of the present invention is to provide an aqueous skin and hair cosmetic that stimulates hair matrix cells through osmotic pressure and promotes hair growth and deodorizing effects on the scalp, armpits, etc. (Means for Solving the Problems) Next, a specific configuration for solving the above-mentioned technical problems will be described. The present invention is based on the following reasons. In other words, the causes of various symptoms such as inflammation, pigmentation, and alopecia, which are lesions on the human skin, are related to various factors such as ultraviolet rays and chemical substances, and changes at the cellular level are limited. The root cause of this problem can be said to be a disorder of the mitochondrial membrane or cell membrane, which is one of the intracellular organelles. In other words, damage to the mitochondrial membrane causes inhibition of intracellular respiration, which reduces the production of ATP (adenosine triphosphate), which is a source of cellular activity. This lack of ATP reduces the active transport function of the cell membrane, resulting in a decline in the ability to transport substances between cells and interstitial fluid. This causes a shortage of nutritional substances such as glucose within the cells,
This in turn leads to a decrease in ATP production, creating a vicious cycle. There are various causes for the above-mentioned changes at the cellular level.In particular, in skin cells, in many cases excluding congenital abnormalities, it is caused by lesions in capillaries or blood circulation disorders due to pressure, etc. thing,
Possible causes include disturbance of osmotic pressure homeostasis due to high accumulation of physiological substances, and a mixture of both. Therefore, if the cause of such damage is removed, cells will be able to carry out normal activities. In particular, cells in the epidermis are susceptible to damage due to their nature of being in contact with the outside world, and this reduces cell activity, resulting in the body's own natural healing power. There may be situations in which recovery is likely to be difficult. Therefore, in order to improve this situation, the present invention creates an environment similar to the interstitial fluid of skin cells on the skin surface and uses electrolyte balance and osmotic pressure balance to remove damaged cells from the surface layer of the skin. Therefore, in the present invention, the components of sodium chloride, glucose, and dextran are melted into the aqueous phase components at a temperature of 50 to 60°C. According to the present invention, the amount of sodium chloride blended is 1 to 10% by weight of the total to ensure effectiveness of osmotic pressure balance and electrolyte balance for the skin, that is, activation of skin cells. Next, the amount of glucose blended is 20 to 30% by weight of the whole for the same reason as the inorganic salt. Furthermore, the amount of dextran blended is 5 to 30% by weight of the whole. The aqueous phase component does not contain any water-soluble oils such as propylene glycol, dipropylene glycol, etc., which are used in the production of ordinary external preparations including cosmetics, and is oil-free and is produced only with pure water. And these sodium chloride, glucose,
When mixing each component of dextran with the aqueous phase component, in order to completely dissolve each component,
Carry out at a temperature of 60°C. (Function) The present invention is configured as described above, and therefore, by applying the solution to the epidermis and leaving it on the epidermis without irritating the skin, interstitial fluid is circulated to subcutaneous cells by applying osmotic pressure, and subcutaneous Various skin diseases can be improved by promoting active cell division. Therefore, it is effective for external skin diseases for which it has been difficult to cure and improve until now, such as hyperpigmentation and male and female alopecia, which are various diseases caused by Trichophyton. (Example) Sodium chloride 10% (weight ratio) Glucose 25% Dextran 30% The above components were mixed and dissolved in water 35% (weight ratio) at a temperature of 50 to 60°C to form an aqueous solution. In order to detect the efficacy of the topical preparation of the present invention, a topical preparation having the above-mentioned composition was manufactured and administered to 30 adult women suffering from hyperpigmentation and redness and 30 adult men suffering from alopecia for 6 months. A wide range of efficacy tests were conducted. (Efficacy results) The effects of this are: Yes...2 points, Somewhat good...1 points
Points, None...The score is calculated as 0 points, and the effectiveness is expressed as (total points/60) x 100.The results are shown in the table below (the numbers in parentheses in the table indicate the effectiveness). show).

【表】 (発明の効果) 本発明は、 塩化ナトリウムを全体の重量比で1〜10%と
し、ブドウ糖を全体の重量比で20〜30%とし、デ
キストランを全体の重量比で5〜30%とし、これ
らの塩化ナトリウム、ブドウ糖、デキストランの
各成分を、50〜60℃の温度で水相成分に溶解した
ことにより、皮膚細胞間質液と同様な環境を皮膚
表面に作り出すことに成功した。 この皮膚細胞間質液と同様な環境は、塩化ナト
リウム等の無機塩や、ブドウ糖等の天然糖、或い
は血漿などが有する、単体の効能を遥かに越える
ものであり、従来期待されていた皮膚の殺菌、
消毒作用、皮膜作用、皮膚の水分の蒸発を防
止して保湿の促進作用等の効能を有するのみに止
どまらず、皮膚疾患に適応した効能が自ら選択的
に作用し、過剰な使用によつても副作用の虞もな
い極めて安全な外用剤となつた。 このことから、ミトコンドリアの膜の障害によ
つて生じる、細胞内呼吸の阻害や、細胞の活動源
たるATP(アデノシン3リン酸)の産生の低下を
防止することができ、電解質バランス、浸透圧バ
ランスを保ち、皮膚の表層からも障害細胞の正常
化を促進することが可能になつた。 したがつて、皮膚に対する浸透圧が発揮され、
シミ、赤ら顔の場合は皮下細胞を刺激、分裂させ
て治癒に導き、また、頭皮、ワキガ等に塗布する
ことにより、浸透圧の応用によつて毛母細胞を刺
激し、発毛及び脱臭作用が促進されるものであ
る。 更に、本発明に係る電解質バランス、浸透圧バ
ランスによる皮膚細胞活性促進外用剤は、従来の
外用剤とは全く異なる新規なものであり、その効
果は驚異的なものである。特に、女性の色素沈着
症の改善、男性の脱毛症の改善、肝班、赤ら顔の
改善等の従来その治癒が困難なものとされていた
諸疾患の治癒に極めて効果があり、また、その治
癒率からみても、更には今日、悩み続けている
人々の期待からみても、本発明の意義は極めて大
きく、人類に大きく貢献するものである。
[Table] (Effects of the invention) In the present invention, sodium chloride is 1 to 10% by weight of the whole, glucose is 20 to 30% by weight of the whole, and dextran is 5 to 30% by weight of the whole. By dissolving these components, sodium chloride, glucose, and dextran, in the aqueous phase components at a temperature of 50 to 60°C, they succeeded in creating an environment similar to the interstitial fluid of skin cells on the skin surface. This environment similar to the interstitial fluid of skin cells far exceeds the efficacy of inorganic salts such as sodium chloride, natural sugars such as glucose, or plasma alone, and has previously been expected to improve skin health. Sterilization,
It not only has the effects of disinfection, film action, preventing the evaporation of water from the skin and promoting moisturizing, but also has effects that are adapted to skin diseases and acts selectively on its own, making it difficult to overuse. It has become an extremely safe topical drug with no risk of side effects even if it gets wet. Therefore, it is possible to prevent inhibition of intracellular respiration and decrease in the production of ATP (adenosine triphosphate), which is a source of cellular activity, caused by damage to the mitochondrial membrane, and to maintain electrolyte balance and osmotic pressure balance. It has now become possible to maintain normalization of damaged cells even from the surface layer of the skin. Therefore, osmotic pressure against the skin is exerted,
In the case of age spots and redness, it stimulates and divides subcutaneous cells, leading to healing. Also, by applying it to the scalp, armpits, etc., it stimulates hair matrix cells by applying osmotic pressure, resulting in hair growth and deodorizing effects. It is promoted. Furthermore, the external preparation for promoting skin cell activity through electrolyte balance and osmotic pressure balance according to the present invention is completely new and different from conventional external preparations, and its effects are surprising. In particular, it is extremely effective in curing various diseases that were previously thought to be difficult to cure, such as improving pigmentation in women, alopecia in men, liver spots, and redness. The present invention is of extremely great significance, both in terms of economic performance and the expectations of people who continue to suffer today, and will greatly contribute to humanity.

Claims (1)

【特許請求の範囲】[Claims] 1 塩化ナトリウムを全体の重量比で1〜10%と
し、ブドウ糖を全体の重量比で20〜30%とし、デ
キストランを全体の重量比で5〜30%とし、これ
らの塩化ナトリウム、ブドウ糖、デキストランの
各成分を、50〜60℃の温度で水相成分に溶解した
ことを特徴とする水性皮膚及び毛髪化粧料。
1 Sodium chloride is 1 to 10% by weight, glucose is 20 to 30% by weight, and dextran is 5 to 30% by weight. An aqueous skin and hair cosmetic characterized in that each component is dissolved in an aqueous phase component at a temperature of 50 to 60°C.
JP60087988A 1985-04-24 1985-04-24 External agent for stimulation skin cell activity Granted JPS61246130A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60087988A JPS61246130A (en) 1985-04-24 1985-04-24 External agent for stimulation skin cell activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60087988A JPS61246130A (en) 1985-04-24 1985-04-24 External agent for stimulation skin cell activity

Publications (2)

Publication Number Publication Date
JPS61246130A JPS61246130A (en) 1986-11-01
JPH0212443B2 true JPH0212443B2 (en) 1990-03-20

Family

ID=13930191

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60087988A Granted JPS61246130A (en) 1985-04-24 1985-04-24 External agent for stimulation skin cell activity

Country Status (1)

Country Link
JP (1) JPS61246130A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007151932A (en) * 2005-12-07 2007-06-21 Transcutaneous Technologies Inc Iontophoretic apparatus

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63229068A (en) * 1987-03-17 1988-09-22 新技術事業団 Electrical stimulation wound therapy device
US5116605A (en) * 1989-03-09 1992-05-26 Alt John P Composition and skin treatment method therewith for mitigating acne and male-pattern baldness
JPH05117158A (en) * 1991-10-22 1993-05-14 Sasaki Kagaku Yakuhin Kk External preparation composition for skin
GB9222772D0 (en) * 1992-10-30 1992-12-09 Unilever Plc Cosmetic composition
JP2920611B2 (en) * 1995-12-11 1999-07-19 株式会社シーエーシー Topical treatment for dermatitis
JP2001139477A (en) * 1999-11-17 2001-05-22 Coherent Technology:Kk Tissue cell growth promoting solution at the wound site

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5799M (en) * 1966-03-22 1968-03-25
US3859436A (en) * 1968-10-02 1975-01-07 Kolmar Laboratories Sugar composition for topical application
US3777597A (en) * 1970-04-29 1973-12-11 Pharmachem Corp Method of shaving employing an aqueous solution of dextran

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007151932A (en) * 2005-12-07 2007-06-21 Transcutaneous Technologies Inc Iontophoretic apparatus

Also Published As

Publication number Publication date
JPS61246130A (en) 1986-11-01

Similar Documents

Publication Publication Date Title
JP2681527B2 (en) Topical for promoting cell activity
KR100950524B1 (en) Topical Glycopyrrolate Products
US5496827A (en) Compositions for the transdermal delivery of nutrients
US5853732A (en) Pharmaceutical compositions containing kukui nut oil
US20230055512A1 (en) Method of treatment of topical dermatologic acne using a cream composition and method of manufacture
EP0308210A1 (en) Topical treatment of diseased skin disorders
KR100673044B1 (en) Topical Compositions for Transdermal Administration
US20060222689A1 (en) Skin care compositions and methods
US20110236503A1 (en) Topical Skincare Composition
CN102688483B (en) A composition for treating skin diseases, a preparation containing the composition and a preparation method thereof
JPH0212443B2 (en)
CN103463627A (en) Oral care composition containing heat-resistant superoxide dismutase and growth factors
JP2013163681A (en) Composition for percutaneous and transmucosal absorption of carbon dioxide
JP5164438B2 (en) Carbon dioxide transdermal / mucosal absorption composition
EP1752132A2 (en) Skin cosmetic compositions
JP5699184B2 (en) Carbon dioxide transdermal / mucosal absorption composition
JP2766811B2 (en) Aqueous skin external preparation
KR0141930B1 (en) External preparation for cell activation
ES2214066T3 (en) PREPARATION OF KHELLINA FOR THE TOPICAL THERAPY OF PSORIASIS, ITS SUBTIPOS, SPECIAL FORMS, AS WELL AS THE TOPIC THERAPY OF ECZEMAS.
RU2325900C2 (en) Skin composition of external application
KR20070006626A (en) Local composition of skin
ITLI20110005A1 (en) COMPOSITION FOR THE CARE OF PSORIASIS AND RELATED SKIN DISEASES
RU2190388C1 (en) Preparation on base of tea tree oil (versions)
JP5993336B2 (en) Carbon dioxide transdermal / mucosal absorption composition
BR102023017423A2 (en) EMOLLIENT COMPOSITIONS FOR SKIN AND CUTICLE CARE

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term